- Home
- NMT vs SGMT Comparison
NMT vs SGMT Comparison
Compare NMT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- SGMT
- Stock Information
- Founded
- NMT 1993
- SGMT 2006
- Country
- NMT United States
- SGMT United States
- Employees
- NMT N/A
- SGMT N/A
- Industry
- NMT Finance/Investors Services
- SGMT
- Sector
- NMT Finance
- SGMT
- Exchange
- NMT Nasdaq
- SGMT Nasdaq
- Market Cap
- NMT 110.6M
- SGMT 131.4M
- IPO Year
- NMT N/A
- SGMT 2023
- Fundamental
- Price
- NMT $11.73
- SGMT $8.72
- Analyst Decision
- NMT
- SGMT Strong Buy
- Analyst Count
- NMT 0
- SGMT 6
- Target Price
- NMT N/A
- SGMT $23.17
- AVG Volume (30 Days)
- NMT 19.1K
- SGMT 3.2M
- Earning Date
- NMT 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- NMT 3.21%
- SGMT N/A
- EPS Growth
- NMT N/A
- SGMT N/A
- EPS
- NMT N/A
- SGMT N/A
- Revenue
- NMT N/A
- SGMT N/A
- Revenue This Year
- NMT N/A
- SGMT N/A
- Revenue Next Year
- NMT N/A
- SGMT N/A
- P/E Ratio
- NMT N/A
- SGMT N/A
- Revenue Growth
- NMT N/A
- SGMT N/A
- 52 Week Low
- NMT $9.05
- SGMT $1.73
- 52 Week High
- NMT $10.93
- SGMT $9.60
- Technical
- Relative Strength Index (RSI)
- NMT 36.79
- SGMT 74.80
- Support Level
- NMT $11.54
- SGMT $6.56
- Resistance Level
- NMT $12.20
- SGMT $9.60
- Average True Range (ATR)
- NMT 0.19
- SGMT 1.13
- MACD
- NMT -0.06
- SGMT 0.29
- Stochastic Oscillator
- NMT 3.03
- SGMT 85.71
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.